AstraZeneca and Cilag, an affiliate of Johnson & Johnson, have entered into an agreement for AstraZeneca to divest the rights to Rhinocort Aqua outside the US.
Myanmar authorities have seized K2.8 billion worth of counterfeit and expired drugs.
India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.
Teva and Regeneron Pharmaceuticals have combined to develop and commercialise fasinumab, a novel nerve growth factor (NGF) antibody.
Pharmaceutical pay-for-delay deals worth less than around $10 million are unlikely to be challenged by the authorities in US courts, according to a speaker at the 2016 AIPPI World Congress in Milan.
Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.
Japan’s government officials have warned the UK that the Asian country may reconsider its research and development activities in the UK following Brexit.
Chugai Pharmaceutical and Fuji Pharma have entered into an agreement to transfer the rights to the manufacture and marketing of cancer drug Vesanoid in Japan.
UK-based company AstraZeneca will have to pay $5.5 million to resolve a bribery case after allegedly falsely rewarding healthcare officials in China and Russia.
The European Medicines Agency has accepted pharmaceutical company Mylan’s request to review its application for a biosimilar of Herceptin.